Last reviewed · How we verify
NCT05418465
Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy
NA trial testing Huangqi Guizhi Wuwu decoction in Diabetic Nephropathies in 100 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | The First Affiliated Hospital of Dalian Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 26 January 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Huangqi Guizhi Wuwu decoction — full drug profile →
- Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
Conditions studied
- Diabetic Nephropathies — all drugs for Diabetic Nephropathies →
Sponsor
The First Affiliated Hospital of Dalian Medical University
Who can join
Adults 18 to 75, any sex, with Diabetic Nephropathies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05418465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Huangqi Guizhi Wuwu decoction
Trials testing the same drug.
- NCT04261920 — Clinical Trial Scheme of Huangqi Guizhi Wuwu Decoction · Phase 4 · unknown
Other recruiting trials for Diabetic Nephropathies
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07187713 — ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases · Phase 4 · recruiting
- NCT06778018 — Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy · NA · recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06431477 — Efficacy and Safety of Telmisartan Compared With Losartan · Phase 4 · recruiting
Other The First Affiliated Hospital of Dalian Medical University trials
Trials by the same sponsor.
- NCT07397390 — an Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vesse · enrolling by invitation
- NCT06836999 — Deep Sedation in Catheter Ablation of Atrial Fibrillation · NA · not yet recruiting
- NCT06356701 — Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC · Phase 1 · unknown
- NCT06250842 — Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study · recruiting
- NCT06056973 — Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05418465 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Dalian Medical University
- Last refreshed: 14 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05418465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing